Ketoconazole
| 證據等級: L5 | 預測適應症: 1 個 |
目錄
Ketoconazole: From Fungal Infections to Acne
One-Sentence Summary
Ketoconazole is an imidazole-class antifungal agent, originally developed and marketed for the treatment of fungal infections. The TxGNN model predicts it may be effective for Acne (Acne Vulgaris), with 1 clinical trial and 15 publications currently identified, though most of this evidence remains mechanistic, in vitro, or drawn from tangential indications rather than confirmatory acne trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Fungal infections (imidazole antifungal agent; specific licensed indication text not available in current dataset) |
| Predicted New Indication | Acne (Acne Vulgaris) |
| TxGNN Prediction Score | 99.80% |
| Evidence Level | L3 |
| Finland Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, ketoconazole is an imidazole antifungal agent that inhibits fungal cytochrome P450-dependent 14α-demethylase, disrupting ergosterol synthesis in fungal cell membranes; its efficacy in fungal infections is well established, and mechanistically it may be applicable to acne through a distinct, non-antifungal pathway.
Acne vulgaris pathophysiology involves Cutibacterium acnes (formerly Propionibacterium acnes), a bacterium whose secreted lipase breaks down sebum triglycerides into free fatty acids that trigger follicular inflammation. In vitro evidence (PMID 28111792) demonstrates that ketoconazole directly inhibits this C. acnes lipase activity and also suppresses bacterial growth, offering a mechanistic link to acne that is independent of its antifungal properties. This is reinforced by a related in vitro study (PMID 20045949) showing azole antifungals have activity against P. acnes isolates from acne patients.
A secondary, weaker rationale comes from ketoconazole's anti-androgenic activity, which has been studied in the context of Cushing's syndrome (via levoketoconazole) and could theoretically reduce sebum production. However, this evidence is derived from a different patient population and indication, not from acne trials directly, so it should be considered supportive rather than confirmatory.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT07237763 | Phase NA | Active, not recruiting | 52 | Randomized comparison of topical ketoconazole 2% cream vs. topical adapalene 2% cream in mild comedonal and papulopustular acne, assessing whether ketoconazole is a viable alternative to retinoids with fewer side effects; results not yet published. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 28111792 | 2017 | Mechanistic/In vitro | Microbiology and Immunology | Ketoconazole inhibits P. acnes lipase activity, a key enzyme in acne-related inflammation; proposed as a potential alternative acne treatment. |
| 20045949 | 2010 | In vitro study | Biological & Pharmaceutical Bulletin | Azole antifungals, including ketoconazole, show in vitro activity against P. acnes isolated from acne vulgaris patients. |
| 12566804 | 2003 | Review | Dermatology (Basel) | Overview of systemic acne treatments; contextualizes antimicrobial approaches for papulopustular acne amid rising antibiotic resistance. |
| 8593718 | 1995 | Clinical/diagnostic study | Clinical and Experimental Dermatology | Pityrosporum (Malassezia) folliculitis is frequently misdiagnosed as acne vulgaris, highlighting a differential diagnosis relevant to antifungal therapy. |
| 8629828 | 1996 | Case report | Archives of Dermatology | Neonatal Malassezia furfur pustulosis associated with papulopustular facial eruptions resembling neonatal acne. |
| 8255067 | 1993 | Review | The Keio Journal of Medicine | Reviews Pityrosporum ovale-associated skin diseases, including folliculitis often confused with acne. |
| 23600337 | 2013 | Review | FP Essentials | Reviews common infant skin rashes including neonatal and infantile acne. |
| 39622522 | 2024 | Formulary survey | Southern Medical Journal | Analyzes dermatologic diagnosis and medication distribution patterns, including acne management, at a free clinic. |
| 32872149 | 2020 | Review | Pharmaceuticals (Basel) | Reviews adapalene, the comparator drug in NCT07237763, and its established role as first-line acne therapy. |
| 19445767 | 2009 | Review | BMJ Clinical Evidence | Reviews PCOS, noting acne as an associated hyperandrogenic symptom; not directly about ketoconazole treatment. |
Finland Market Information
Ketoconazole is currently not marketed in Finland — no marketing authorization records are available in this dataset (0 authorizations).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for ketoconazole in acne currently rests on in vitro/mechanistic studies and a single small, non-phased, still-ongoing trial (L3) — there is no completed RCT directly evaluating ketoconazole for acne. Critical safety data (warnings, contraindications, drug interactions) are entirely unavailable, which blocks even a preliminary safety assessment.
To proceed, the following is needed:
- Package insert warnings/contraindications and DDI data (currently a blocking data gap)
- Confirmed mechanism-of-action documentation from DrugBank
- Completed results from NCT07237763 (expected completion 2025-12)
- Additional RCT-level evidence directly evaluating ketoconazole (not levoketoconazole or Cushing's-population data) in acne vulgaris
- Formal DDI review, given known CYP3A4 interaction potential of imidazole antifungals
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.